Effect of zinc supplementation on tuberculosis therapy

Effect of zinc supplementation in improving pulmonary tuberculosis patients in Qom

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112178429N1

Enrollment

100

Registered

2012-08-09

Start date

2012-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis. infections due to Mycobacterium tuberculosis and Mycobacterium bovis

Interventions

Treatment - Drugs

Intervention 1: Dietary Zinc supplement ,30 mg( zinc) every 48 h for 6 month. Intervention 2: Placebo every 48 h for 6 months.

Dietary Zinc supplement ,30 mg( zinc) every 48 h for 6 month

Placebo every 48 h for 6 months

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria includes having tuberculosis and filling the informed consent Exclusion criteria includes getting diseases such as cancer, stroke, immiunosupprision diseases and not taking mineral supplement or placebo

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Stop fever. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Physical exam.;Radiological signs. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Chest radiology.;Smear negative. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Smear.;Stop coughing. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Physical exam.	—

Measure

Time frame

Stop fever. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Physical exam.;Radiological signs. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Chest radiology.;Smear negative. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Smear.;Stop coughing. Timepoint: At the baseline ,2 month and 6 month later. Method of measurement: Physical exam.

—

Secondary

Measure	Time frame
Serum Zinc. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: Atomic Absorption.;Serum Copper. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: Atomic Absorption.;Serum Fe. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum ALK. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum Albumin. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Body Mass Index. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: weight(kg)/height2 (m2).;Serum SGPT. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum SGOT. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum total protein. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.	—

Measure

Time frame

Serum Zinc. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: Atomic Absorption.;Serum Copper. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: Atomic Absorption.;Serum Fe. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum ALK. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum Albumin. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Body Mass Index. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: weight(kg)/height2 (m2).;Serum SGPT. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum SGOT. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.;Serum total protein. Timepoint: At baseline ,2 month and 6 month later. Method of measurement: RA 1000.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Pourfallah

Institute Pasteur of Iran

fpourfallah@pasteur.ac.ir+98 21 6640 2770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026